Last reviewed · How we verify
ZEN003694 (zen003694)
PO QD
ZEN003694 is a selective androgen receptor degrader (SARD) approved for castration-resistant prostate cancer. It works by binding to the androgen receptor and triggering its rapid degradation rather than simple blockade, offering potential advantages in overcoming resistance mechanisms seen with traditional androgen receptor inhibitors.
At a glance
| Generic name | zen003694 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | PO QD |
| Therapeutic area | Oncology |
| Phase | discontinued |
Approved indications
Pipeline indications
- Triple Negative Breast Cancer — discontinued
Common side effects
Key clinical trials
- ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer (Phase 2)
- A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZEN003694 CI brief — competitive landscape report
- ZEN003694 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI